Unknown

Dataset Information

0

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.


ABSTRACT: With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep molecular response (DMR) with imatinib. Dasatinib, a second-generation TKI, is more potent than imatinib in the inhibition of BCR-ABL1 tyrosine kinase in vitro and more effective in CP-CML patients who do not achieve an optimal response with imatinib treatment.In the present study, we attempted to investigate whether switching the treatment from imatinib to dasatinib can induce DMR in 16 CP-CML patients treated with imatinib for at least two years who achieved a major molecular response (MMR) with detectable levels of BCR-ABL1 transcripts.The rates of achievement of DMR at 1, 3, 6 and 12 months after switching to dasatinib treatment in the 16 patients were 44% (7/16), 56% (9/16), 63% (10/16) and 75% (12/16), respectively. The cumulative rate of achieving DMR at 12 months from initiation of dasatinib therapy was 93.8% (15/16). The proportion of natural killer cells and cytotoxic T cells in peripheral lymphocytes increased after switching to dasatinib. In contrast, the proportion of regulatory T cells decreased during treatment. The safety profile of dasatinib was consistent with previous studies.Switching to dasatinib would be a therapeutic option for CP-CML patients who achieved MMR but not DMR by imatinib, especially for patients who wish to discontinue TKI therapy.

SUBMITTER: Shiseki M 

PROVIDER: S-EPMC5608785 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.

Shiseki Masayuki M   Yoshida Chikashi C   Takezako Naoki N   Ohwada Akira A   Kumagai Takashi T   Nishiwaki Kaichi K   Horikoshi Akira A   Fukuda Tetsuya T   Takano Hina H   Kouzai Yasuji Y   Tanaka Junji J   Morita Satoshi S   Sakamoto Junichi J   Sakamaki Hisashi H   Inokuchi Koiti K  

International journal of clinical oncology 20170526 5


<h4>Background</h4>With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep molecular response (DMR) with imatinib. Dasatinib, a second-generation TKI, is more potent than imatinib in the inhibition of BCR-ABL1 tyrosine kinase in vitro and more effective in CP-CML patients  ...[more]

Similar Datasets

| S-EPMC4559757 | biostudies-literature
| S-EPMC3041785 | biostudies-literature
| S-EPMC6269287 | biostudies-literature
| S-EPMC3156347 | biostudies-literature
| S-EPMC5625826 | biostudies-other
| S-EPMC8307111 | biostudies-literature
| S-EPMC7387297 | biostudies-literature
| S-EPMC5851790 | biostudies-literature
| S-EPMC10598002 | biostudies-literature
| S-EPMC9240361 | biostudies-literature